Varenicline increases smoking abstinence at 6 months to a year compared with placebo or bupropion; nausea is the most commonly reported adverse effect

Affiliations

Comment

Mehmet Sofuoglu et al. Evid Based Med. 2011 Aug.

. 2011 Aug;16(4):113-4.

doi: 10.1136/ebm1200. Epub 2011 Mar 9.

¹ VA Connecticut Healthcare System & Yale Department of Psychiatry, West Haven, Connecticut, USA. mehmet.sofuoglu@yale.edu

No abstract available

Conflict of interest statement

Conflicting interests

MS AND DD have no conflicting interests.

Nicotine receptor partial agonists for smoking cessation.
Cahill K, Stead LF, Lancaster T. Cahill K, et al. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006103. doi: 10.1002/14651858.CD006103.pub4. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. doi: 10.1002/14651858.CD006103.pub5. PMID: 21154363 Updated.

1. Sofuoglu M, Herman AI, Mooney M, Waters AJ. Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans. Psychopharmacology. 2009 Nov;207(1):153–162. - PMC - PubMed
1. Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Archives of general psychiatry. 2004 Nov;61(11):1107–1115. - PubMed